Dr. Robert Giugliano, MD, discusses data released from the FOURIER study, an analysis evaluating patient-reported cognition in high-risk heart disease patients, including patients achieving low levels of LDL-cholesterol after an average of two years of treatment. The data were published in the “Journal of the American College of Cardiology” May 2020
Dr. Robert Patrick Giugliano, MD, MSc, Associate Professor of Medicine, Harvard Medical School; Brigham and Women’s Hospital, Department of Medicine, Cardiovascular. Dr. Robert Giugliano’s areas of research interests include novel antithrombotic and fibrinolytic agents for acute coronary syndromes (ACS), lipid-lowering therapies, and the assessment of outcomes in patients with ACS. He has authored over 100 articles, 25 editorials/book chapters, and given over 150 lectures nationally and internationally. Dr. Giugliano has served as the lead investigator and physician-in-charge of six multicenter phase-II or III trials (TIMI 15A, TIMI 15B, INTEGRITI-TIMI 20, ADVANCE MI-TIMI 29, ANTHEM-TIMI 32, EARLY-ACS TIMI 39). In addition, he has worked closely with Dr. Elliott Antman and Dr. Christopher Cannon coordinating another six international trials and continues to serve as the local investigator as a participating hospital for four additional studies. He is a co-investigator of five international thrombolytic studies working with Drs. Antman (TIMI 14, InTIME-II, and InTIME-IIb) and Cannon (TIMI 10B, ASSENT I), and one international trial with Dr Cannon in lipid-lowering therapies (IMPROVE-IT).Outside of TIMI, he continues to collaborate with independent research groups (Massachusetts General Hospital, Montreal Heart Institute) studying clinical practice guidelines and risk stratification in unstable angina.